cas 1442437-21-9|| where to buy 4-hydroxy-6-oxo-1H-pyridazine-3-carboxylic acid

Nom du produit:4-hydroxy-6-oxo-1H-pyridazine-3-carboxylic acid

IUPAC Name:4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

Unité d'emballage	Stock disponible	Prix($)
CM325395-5g	in stock	ȺưǊ
CM325395-10g	in stock	ǜțƦ
CM325395-25g	in stock	ǊȬǊ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1442437-21-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1442437-21-9; Formule moléculaire:C5H4N2O4; Point de fusion:-; Code SMILES:O=C(C(C(O)=C1)=NNC1=O)O; Densité:

: Numéro de catalogue:CM325395; Poids moléculaire:156.1; Point d'ébullition:; N° Mdl:MFCD30489098; Stockage:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Deucravacitinib; BMY announced new four-year Sotyktu (deucravacitinib) data demonstrating durable response rates and consistent safety in moderate-to-severe plaque psoriasis. Deucravacitinib is a specific, oral, intracellular TYK2 inhibitor that targets immune responses driven by type 1 IFN and IL-23 that contribute to psoriasis pathogenesis, including IL-17 production and Th1/Th17 polarization.